APOLIPROTEIN-E PHENOTYPE IS RELATED TO MACROANGIOPATHY AND MICROANGIOPATHY IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS

被引:86
作者
UKKOLA, O
KERVINEN, K
SALMELA, PI
VONDICKHOFF, K
LAAKSO, M
KESANIEMI, YA
机构
[1] UNIV OULU,DEPT INTERNAL MED,SF-90220 OULU,FINLAND
[2] UNIV OULU,BIOCTR OULU,SF-90100 OULU 10,FINLAND
[3] UNIV KUOPIO,DEPT INTERNAL MED,SF-70211 KUOPIO 21,FINLAND
[4] UNIV OULU,DEPT OPHTHALMOL,SF-90100 OULU 10,FINLAND
基金
芬兰科学院;
关键词
APOLIPOPROTEIN-E; NON-INSULIN-DEPENDENT DIABETES-MELLITUS; MACROANGIOPATHY; MICROANGIOPATHY; LIPOPROTEINS; CHOLESTEROL; TRIGLYCERIDES; LIPOPROTEIN(A);
D O I
10.1016/0021-9150(93)90096-D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of apolipoprotein E (apo E) in modulating the susceptibility of individuals with non-insulin-dependent diabetes mellitus (NIDDM) to atherosclerotic vascular disease was studied in 143 male and 128 female patients with NIDDM. The data show that the apolipoprotein phenotype E2 somehow protects from macrovascular complications in NIDDM both in men and women. E2 also tends to protect from microvascular complications. In contrast, apo E phenotypes E4/4 and E4/3 tend to increase the risk for macroangiopathy in NIDDM patients. The lower prevalence of macroangiopathy in the subjects with E2 was associated with lower plasma total and LDL cholesterol concentrations and low plasma lipoprotein(a) levels. Overall, this study demonstrates the role of the apo E phenotype to modulate the risk for diabetic complications in patients with NIDDM. The confirmation of the association of apo E polymorphism with diabetic complications warrants, however, long-term follow-up studies.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 37 条
[1]  
ASSMANN G, 1984, CLIN CHEM, V30, P641
[2]  
BERG K, 1963, ACTA PATHOL MIC SC, V59, P369
[3]  
CUMMING AM, 1984, CLIN GENET, V25, P310
[4]   APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS [J].
DAVIGNON, J ;
GREGG, RE ;
SING, CF .
ARTERIOSCLEROSIS, 1988, 8 (01) :1-21
[5]   ALBUMINURIA REFLECTS WIDESPREAD VASCULAR DAMAGE - THE STENO HYPOTHESIS [J].
DECKERT, T ;
FELDTRASMUSSEN, B ;
BORCHJOHNSEN, K ;
JENSEN, T ;
KOFOEDENEVOLDSEN, A .
DIABETOLOGIA, 1989, 32 (04) :219-226
[6]   APOLIPOPROTEIN-E POLYMORPHISM AFFECTS PLASMA-LEVELS OF LIPOPROTEIN(A) [J].
DEKNIJFF, P ;
KAPTEIN, A ;
BOOMSMA, D ;
PRINCEN, HMG ;
FRANTS, RR ;
HAVEKES, LM .
ATHEROSCLEROSIS, 1991, 90 (2-3) :169-174
[7]  
EHNHOLM C, 1986, J LIPID RES, V27, P227
[8]   APOLIPOPROTEIN-E POLYMORPHISM AND HYPERLIPEMIA IN TYPE-II DIABETICS [J].
ETO, M ;
WATANABE, K ;
IWASHIMA, Y ;
MORIKAWA, A ;
OSHIMA, E ;
SEKIGUCHI, M ;
ISHII, K .
DIABETES, 1986, 35 (12) :1374-1382
[9]   MORTALITY FROM CORONARY HEART-DISEASE AND STROKE IN RELATION TO DEGREE OF GLYCEMIA - THE WHITEHALL STUDY [J].
FULLER, JH ;
SHIPLEY, MJ ;
ROSE, G ;
JARRETT, RJ ;
KEEN, H .
BMJ-BRITISH MEDICAL JOURNAL, 1983, 287 (6396) :867-870
[10]   LACK OF CHANGE OF LIPOPROTEIN (A) CONCENTRATION WITH IMPROVED GLYCEMIC CONTROL IN SUBJECTS WITH TYPE-II DIABETES [J].
HAFFNER, SM ;
TUTTLE, KR ;
RAINWATER, DL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (02) :116-120